首页> 外文期刊>Circulation. Genomic and precision medicine. >Gut Microbiome and Response to Cardiovascular Drugs
【24h】

Gut Microbiome and Response to Cardiovascular Drugs

机译:肠道微生物和心血管反应药物

获取原文
获取原文并翻译 | 示例
           

摘要

The gut microbiome is emerging as an important contributor to both cardiovascular disease risk and metabolism of xenobiotics. Alterations in the intestinal microbiota are associated with atherosclerosis, dyslipidemia, hypertension, and heart failure. The microbiota have the ability to metabolize medications, which can results in altered drug pharmacokinetics and pharmacodynamics or formation of toxic metabolites which can interfere with drug response. Early evidence suggests that the gut microbiome modulates response to statins and antihypertensive medications. In this review, we will highlight mechanisms by which the gut microbiome facilitates the biotransformation of drugs and impacts pharmacological efficacy. A better understanding of the complex interactions of the gut microbiome, host factors, and response to medications will be important for the development of novel precision therapeutics for targeting CVD.gggatherosclerosis, hypertension, metabolomics, microbiota, pharmacogenetics, pharmacokinetics, pharmacologic actions
机译:肠道微生物正成为一个重要的心血管疾病的风险因素和外源性物质的代谢。肠道菌群与相关联动脉粥样硬化、血脂异常、高血压心力衰竭。代谢药物,从而导致改变药物药物动力学和药效学或有毒的形成代谢物可干扰药物响应。他汀类药物和微生物调节反应抗高血压药物。将突出机制肠道微生物促进的生物转化药物和影响药理功效。更好地理解复杂的交互肠道微生物的宿主因素和响应药物将是重要的精密治疗学的新发展针对心血管疾病。代谢组学、微生物群遗传药理学,药物动力学,药物行动

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号